Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCD0503 (Oral Insulin) vs Subcutaneous Regular Human Insulin in Type 1 Diabetes
NCT07634770Phase 1Recruiting
- Sponsor
- Sam Chun Dang Pharm Co., Ltd.
- Start
- May 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCD0503 in type 1 diabetes mellitus (T1D) (8 arms), sponsored by Sam Chun Dang Pharm Co., Ltd. Primary endpoints: Area under the serum insulin concentration curve from 0 to 6 hours, Maximum observed insulin concentration and 2 more. Started May 2026; status: recruiting.
02
Drugs
SCD0503
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07634770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07634770.